Chemotherapy-induced hypersensitivity reactions

Oncology Nursing Forum

Volumn 32, Issue 5, 2005, Pages 1027-1035

  Gobel, Barbara Holmes ^a,b  

^a NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^b RUSH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINE; PLATINUM DERIVATIVE; PODOPHYLLOTOXIN; TAXOID;

DRUG HYPERSENSITIVITY; HUMAN; METHODOLOGY; NEOPLASM; NURSING; ONCOLOGY NURSING; REVIEW; RISK ASSESSMENT; RISK FACTOR;

ANTINEOPLASTIC AGENTS; ASPARAGINE; DRUG HYPERSENSITIVITY; HUMANS; NEOPLASMS; ONCOLOGIC NURSING; PLATINUM COMPOUNDS; PODOPHYLLOTOXIN; RISK ASSESSMENT; RISK FACTORS; TAXOIDS;

EID: 33745394443     PISSN: 0190535X     EISSN: 15380688     Source Type: Journal    
DOI: 10.1188/05.ONF.1027-1035     Document Type: Article

References (52)

1. Aventis Pharmaceuticals Inc. (2003). Taxotere® (docetaxel) injection concentrate [Package insert]. Bridgewater, NJ: Author.
2. Bernstein, B.J. (2000). Docetaxel as an alternative to paclitaxel after acute hypersensitivity reactions. Annals of Pharmacotherapy, 34, 1332-1335.
3. Bhargava, P., Gammon, D., & McCormick, M.J. (2004). Hypersensitivity and idiosyncratic reactions to oxaliplatin [Letter]. Cancer, 100, 211-212.
4. Blumenreich, M.S., Needles, B., Yagoda, A., Sogani, P., Grabstald, H., & Whitmore, W.F., Jr. (1982). Intravesical cisplatin for superficial bladder tumors. Cancer, 50, 863-865.
5. Brandi, G., Pantaleo, M.A., Galli, C., Falcone, A., Antonuzzo, A., Mordenti, P., et al. (2003). Hypersensitivity reactions related to oxaliplatin (OHP). British Journal of Cancer, 89, 477-481.
6. Bristol-Myers Squibb Company. (2003). Taxol® (paclitaxel) injection [Package insert]. Princeton, NJ: Author.
7. Brown, A.F. (1998). Therapeutic controversies in the management of acute anaphylaxis. Journal of Accident and Emergency Medicine, 15, 89-95.
8. Cleare, M.J., Hughes, E.G., Jacoby, B., & Pepys, J. (1976). Immediate (type I) allergic responses to platinum compounds. Clinical Allergy, 6, 183-195.
9. de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., et al. (2000). Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. Journal of Clinical Oncology, 18, 2938-2947.
10. Denis, L. (1983). Anaphylactic reactions to repeated intravesical instillation with cisplatin [Letter]. Lancet, 1, 1378-1379.
11. Dold, F., Hoey, D., Carberry, M., Musket, A., Freidberg, V., & Mitchell, E. (2002). Hypersensitivity in patients with metastatic colorectal carcinoma undergoing chemotherapy with oxaliplatin [Abstract 1478]. Proceedings of the American Society of Clinical Oncology, 21, 370a.
12. Drain, K.L., & Volcheck, G.W. (2001). Preventing and managing druginduced anaphylaxis. Drug Safety, 24, 843-853.
13. Essayan, D.M., Kagey-Sobotka, A., Colarusso, P.J., Lichtenstein, L.M., Ozols, R.F., & King, E.D. (1996). Successful parenteral desensitization to paclitaxel. Journal of Allergy and Clinical Immunology, 97(1, Pt. 1), 42-46.
14. Fishman, A., Gold, T., Goldberg, A., Confino-Cohen, R., Beyth, Y., Menczer, J., et al. (1999). Effective desensitization protocol to paclitaxel following hypersensitivity reaction. International Journal of Gynecologic Cancer, 9, 156-159.
15. Giacchetti, S., Perpoint, B., Zidani, R., Le Bail, N., Faggiuolo, R., Focan, C., et al. (2000). Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. Journal of Clinical Oncology, 18, 136-147.
16. Gobel, B.H. (2005). Oncologic emergencies. In J.K. Itano & K.N. Taoka (Eds.), Core curriculum for oncology nursing (pp. 383-421). London: Elsevier.
17. Goldberg, A., Confino-Cohen, R., Fishman, A., Beyth, Y., & Altaras, M. (1996). A modified, prolonged desensitization protocol in carboplatin allergy. Journal of Allergy and Clinical Immunology, 98, 841-843.
18. Grosen, E., Siitari, E., Larrison, E., Tiggelaar, C., & Roecker, E. (2000). Paclitaxel hypersensitivity reactions related to bee-sting allergy [Research letters]. Lancet, 355, 288-289.
19. Kellie, S.J., Crist, W.M., Pui, C.H., Crone, M.E., Fairclough, D.L., Rodman, J.H., et al. (1991). Hypersensitivity reactions to epipodophyllotoxins in children with acute lymphoblastic leukemia. Cancer, 67, 1070-1075.
20. Koppler, H., Heymanns, J., & Weide, R. (2001). Dose reduction of steroid premedication for paclitaxel: No increase of hypersensitivity reactions. Onkologie, 24, 283-285.
21. Labovich, T.M. (1999). Acute hypersensitivity reactions to chemotherapy. Seminars in Oncology Nursing, 15, 222-231.
22. Larson, R.A., Fretzin, M.H., Dodge, R.K., & Schiffer, C.A. (1998). Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia. Leukemia, 12, 660-665.
23. Lorenz, W., Reimann, H.J., Schmal, A., Dormann, P., Schwartz, B., Neugebauer, E., et al. (1977). Histamine release in dogs by Cremophor EL and its derivatives: Oxethylated oleic acid is the most effective constituent. Agents and Actions, 7, 63-67.
24. Markman, M., Kennedy, A., Webster, K., Elson, P., Peterson, G., Kulp, B., et al. (1999). Clinical features of hypersensitivity reactions to carboplatin. Journal of Clinical Oncology, 17, 1141.
25. Muller, H.J., Beier, R., Loning, L., Blutters-Sawatzki, R., Dorffel, W., Maass, E., et al. (2001). Pharmacokinetics of native Escherichia coli asparaginase (Asparaginase medac) and hypersensitivity reactions in ALL-BFM 95 reinduction treatment. British Journal of Haemalology, 114, 794-799.
26. Muller, H.J., Loning, L., Horn, A., Schwabe, D., Gunkel, M., Schrappe, M., et al. (2000). Pegylated asparaginase (oncaspar) in children with ALL: Drug monitoring in reinduction according to the ALL/NHL-BFM 95 protocols. British Journal of Haematology, 110, 379-384.
27. Myers, J. (2000). Hypersensitivity reactions to paclitaxel: Nursing interventions. Clinical Journal of Oncology Nursing, 4, 161-163.
28. National Cancer Institute. (2003). Common Terminology Criteria for Adverse Events v 3.0. Retrieved June 8, 2005, from http://ctep.cancer.gov/ reporting/ctc.html
29. Nolte, H., Carstensen, H., & Hertz, H. (1988). VM-26 (teniposide)-induced hypersensitivity and degranulation of basophils in children. American Journal of Pediatric Hematology and Oncology, 10, 308-312.
30. O'Dwyer, P.J., King, S.A., Fortner, C.L., & Leyland-Jones, B. (1986). Hypersensitivity reactions to teniposide (VM-26): An analysis. Journal of Clinical Oncology, 4, 1262-1269.
31. Peereboom, D.M., Donehower, R.C., Eisenhauer, E.A., McGuire, W.P., Onetto, N., Hubbard, J.L.. et al. (1993). Successful retreatment with taxol after major hypersensitivity reactions. Journal of Clinical Oncology, 11, 885-890.
32. Physician's desk reference (55th ed.). (2001). Montvale, NJ: Medical Economics.
33. Polovich, M., White, J.M., & Kelleher, L.O. (2005). Chemotherapy and biotherapy guidelines and recommendations for practice (2nd ed.). Pittsburgh, PA: Oncology Nursing Society.
34. Ramanathan, R.K., Clark, J.W., Kemeny, N.E., Lenz, H.J., Gococo, K.O., Haller, D.G., et al. (2003). Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancer. Journal of Clinical Oncology, 21, 2904-2911.
35. Ream, M., & Tunison, D. (2001). Hypersensitivity reactions. In J.M. Yasko (Ed.), Nursing management of symptoms associated with chemotherapy (5th ed., pp. 271-282). Bala Cynwyd, PA: Meniscus Limited.
36. Rodriguez, T., Baumgarten, E., Fengler, R., Soumpasis, D., & Henze, G. (1995). Long-term infusion of L-asparaginase - An alternative to intramuscular injection? Klinische Padiatrie, 207, 207-210.
37. Rose, P.G., Fusco, N., Fluellen, L., & Rodriguez, M. (1998). Carboplatin hypersensitivity reactions in patients with ovarian and peritoneal carcinoma. International Journal of Gynecological Cancer, 8, 365-366.
38. Runge, J.W., Martinez, J.C., Caravati, E.M., Williamson, S.G., & Hartsell, S.C. (1992). Histamine antagonists in the treatment of acute allergic reactions. Annals of Emergency Medicine, 21, 237-242.
39. Sanofi-Synthelabo, Inc. (2003). Eloxatin® [Package insert]. New York: Author.
40. Shanholtz, C. (2001). Acute life-threatening toxicity of cancer treatment. Critical Care Clinics, 17, 483-502.
41. Shepherd, G.M. (2003). Hypersensitivity reactions to chemotherapeutic drugs. Clinical Reviews in Allergy and Immunology, 24, 253-262.
42. Shlebak, A.A., Clark, P.I., & Green, J.A. (1995). Hypersensitivity and cross-reactivity to cisplatin and analogues. Cancer Chemotherapy and Pharmacology, 35, 349-351.
43. Shukunami, K., Kurokawa, T., Kawakami, Y., Kubo, M., & Kotsuji, F. (1999). Hypersensitivity reactions to intraperitoneal administration of carboplatin in ovarian cancer: The first report of a case. Gynecologic Oncology, 72, 431-432.
44. Sorich, J., Taubes, B., Wagner, A., & Hochster, H. (2004). Oxaliplatin: Practical guidelines for administration. Clinical Journal of Oncology Nursing, 8, 251-256.
45. Stahl, M., Koster, W., & Wilke, H. (2001). Reaction after oxaliplatin - Prevention with corticosteroids? Annals of Oncology, 12, 874.
46. Stone, H.D., Jr., DiPiro, C., Davis, P.C., Meyer, C.F., & Wray, B.B. (1998). Hypersensitivity reactions to Escherichia coli-derived polyethylene glycolate-asparaginase associated with subsequent immediate skin test reactivity to E. coli-derived granulocyte colony-stimulating factor. Journal of Allergy and Clinical Immunology, 101, 429-431.
47. Thomas, M. (2004). Treatment-related hypersensitivity reactions to anti-neoplastic agents: Recognition, prevention, and management [Continuing education monograph and self-test]. Skillman, NJ: American Academy of Continuing Medical Education.
48. Tsavaris, N.B., & Kosmas, C. (1998). Risk of severe acute hypersensitivity reactions after rapid paclitaxel infusion of less than 1 -h duration. Cancer Chemotherapy and Pharmacology, 42, 509-511.
49. United States Pharmacopeial Convention, Inc. (2000). USP dispensing information: Vol. 1: Drug information for the health cure professional (20th ed.). Englewood, CO: Micromedix.
50. Weiss, R.B. (2001). Miscellaneous toxicities. In V.T. De Vita Jr., S. Hellman, & S.A. Rosenberg (Eds.), Cancer: Principles and practice of oncology (6th ed., pp. 2964-2976). Philadelphia: Lippincott Williams and Wilkins.
51. Zanotti, K.M., & Markman, M. (2001). Prevention and management of antineoplastic-induced hypersensitivity reactions. Drug Safety, 24, 767-779.
52. Zanotti, K.M., Rybicki, L.A., Kennedy, A.W., Belinson, J.L., Webster, K.D., Kulp, B., et al. (2001). Carboplatin skin testing: A skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy. Journal of Clinical Oncology, 19, 3126-3129.